Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153172 | 0.87 | ALDH1A1 (0.51) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL20069826 | 0.84 | KMT2A (0.49) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL20069825 | 0.84 | KDM4E (0.48) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL22811913 | 0.82 | LMNA (0.51) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL22030762 | 0.81 | RET (0.47) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL20205857 | 0.80 | RAB9A (0.48) | RETALDH1A1KDM4ELMNARAB9A | |
| SCHEMBL20149644 | 0.73 | CHRNB2 (0.49) | RETKMT2AMEN1 | |
| SCHEMBL20152350 | 0.71 | RET (0.47) | RET | |
| SCHEMBL1348379 | 0.70 | KMT2A (0.61) | ALDH1A1KDM4ELMNARAB9ANPC1 | |
| SCHEMBL31734621 | 0.70 | PIK3CA (0.46) | RETKMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953005-B1 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885ALDH1A1 2868/4885KDM4E 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.